Proteomics partnership to improve treatment of CKD
Filed with ASX · · 2 pages · English
Earlier from Dimerix
- Entitlement Offer Booklet
- Entitlement Offer to raise $5.5 million
- Suspension from Official Quotation
- Dimerix Phase 2a Subgroup Analysis Results
- Ethics Committee Approval for Pharmacokinetic Trial
Later from Dimerix
- DMX-200 Dosage Optimisation Study Successfully Completed
- Results of Entitlement Offer
- Quarterly Review and Appendix 4C
- Oversubscribed Placement to Raise a Further $4.5m
- Half Year Report and Financial Statements
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix